Long-Term Effects of Ozempic

Most people think of Ozempic pens as a quick fix for diabetes or weight loss. But stay on it long enough, and you’ll start to notice changes. Some surprising, others life-altering. Studies reveal that Ozempic’s long-term effects extend far beyond blood sugar readings and scale, affecting everything from your heart to your gut health.

Before you commit to years of treatment, here’s what science says about the long-term effects of Ozempic.

Beneficial Long-Term Effects of Ozempic

Some effects of Ozempic occur early, such as improved blood sugar control, but others may appear later or become more noticeable with prolonged use.

1. Sustained A1c/HbA1c reduction

If you’re living with type 2 diabetes, expect a clinically meaningful A1c reduction with continued use. In the SUSTAIN-6 trial, designed to test cardiovascular safety/benefit, it ran 104 weeks and tracked A1c throughout.

This study followed 3,297 randomized participants. Of these, 98% completed follow-up and 99.6% had their vital status confirmed by the study’s end in March 2016. Treatment adherence was high, with participants on semaglutide taking it for about 86.5% of the study period.

At the start of the study, the average A1c level across all groups was 8.7%. After 104 weeks, patients on semaglutide 0.5 mg saw a drop to 7.6% (-1.1%), and those on 1.0 mg dropped to 7.3% (-1.4%). Placebo groups only fell to 8.3% (-0.4%).

Over the course of the trial, fewer semaglutide patients needed extra diabetes drugs. Insulin was started more than twice as often in the placebo group, demonstrating semaglutide’s ability to control blood sugar and delay intensification of therapy.

Real-world cohorts have similar findings. In a single-center study tracking individuals on injectable semaglutide for up to 720 days (~2 years), the mean A1c level decreased by about 1.15%.

By the end of 2 years, more than half of the patients achieved the target HbA1c of less than or equal to 7%. Improvements in blood sugar control were sustained at 180, 360, 540, and 720 days, and were consistent with the results seen in controlled clinical trials.

2. Long-term weight loss

Across SUSTAIN trials, people commonly lose ~10-15% of initial weight over 1-2 years when therapy is continued. In SUSTAIN-6, lower body weight was also observed versus placebo.

The average starting weight was 92.1 kg (about 203 lbs) across all groups. In the 0.5 mg semaglutide group, participants lost 3.6 kg (7.9 lbs). In the 1.0 mg group, they experienced a loss of 4.9 kg (10.8 lbs). In comparison, the placebo groups saw smaller changes, with a maximum increase of only 0.7 kg (1.5 lbs).

Ozempic can deliver double-digit weight-loss percentages that hold for years, but if you stop taking it, weight regain is common.

In the STEP 1 extension study, following 68 weeks of higher-dose semaglutide 2.4 mg, participants on semaglutide lost an average of 17.3% of their starting weight. However, once treatment ended, weight was regained. By week 120 (one year after stopping), the semaglutide group had regained 11.6 % of their lost weight.

Ozempic changes hunger signals in your brain and slows digestion, so you naturally eat less. Once you stop, these effects disappear and your body may work to restore your previous weight through increased appetite and slower metabolism.

For the best results, plan for Ozempic as a long-term tool or have a solid maintenance strategy (like nutrition and activity) ready before stopping.

3. Heart and kidney protection

Some of Ozempic’s most significant long-term benefits may be in your heart and kidneys, particularly with its most recent approval, which is centered on kidney health.

In the SUSTAIN-6 study, researchers focused on participants who were:

• • Age 50 or older
  • Already had established cardiovascular disease (like prior heart attack, stroke, or peripheral artery disease)
  • Chronic heart failure (NYHA class II or III)
  • Stage 3 or higher chronic kidney disease
  • Age 60 or older with at least one cardiovascular risk factor (e.g., hypertension, high cholesterol, smoking history, etc.).

Semaglutide significantly reduced the combined risk of major cardiovascular events:

• • Cardiovascular death
  • A nonfatal heart attack
  • A nonfatal stroke)

Over the study, 6.6% of people on semaglutide experienced one of these events, compared with 8.9% on placebo. That’s about a 26% lower relative risk for the semaglutide group.

In the FLOW trial, researchers tested whether semaglutide could protect kidney function and reduce serious health risks in people with type 2 diabetes and chronic kidney disease (CKD). This is a group known to have a high risk of kidney failure, heart problems, and early death.

Over about 3.4 years, the risk of serious kidney problems, kidney failure, or death from kidney or heart disease was 24% lower with semaglutide. Other outcomes include:

Following that trial, another study was conducted to focus on the effects of semaglutide on heart failure outcomes in the FLOW trial. A total of 3,533 people with T2D and CKD were randomly assigned to once-weekly semaglutide 1 mg or placebo. Around 19% in each group already had HF at the start.

Over three years, semaglutide meaningfully lowered the risk of heart failure events (27% lower risk) in people with T2D and CKD, with consistent benefits regardless of whether they already had heart failure.

4. Other metabolic improvements

Ozempic’s long-term benefits go beyond blood sugar and weight.

• • Blood pressure: After two years in the SUSTAIN-6 trial, the systolic blood pressure of people taking semaglutide 0.5 mg dropped by 3.4 mm Hg. Those taking the 1.0 mg dose decreased by 5.4 mmHg.

• • Cholesterol and other lipids: Trials report improvements in lipid markers. In one meta-analysis, results showed the following reductions in five lipid markers:

• • Fatty liver: In a 2020 phase 2 biopsy trial, semaglutide increased nonalcoholic steatohepatitis (NASH) resolution (now termed MASH) compared to placebo. In the 2025 phase 3 results (72-week trial), 62.9% achieved resolution of steatohepatitis and 36.8% had fibrosis reduction. Additionally, 32.7% achieved both outcomes.

These effects may not be dramatic individually, but they improve your overall metabolic profile.

5. Anti-inflammatory effects

Emerging studies suggest Ozempic may also fight inflammation. Researchers think it’s through the following pathways:

Reducing inflammatory cytokines

Cytokines are chemical messengers used by immune cells. Some, like IL-6 and TNF-alpha, are “pro-inflammatory” and cause tissue damage when they stay elevated for too long.

Evidence from animal studies:

Evidence from human studies:

Modulating immune system responses

Semaglutide may also change how immune cells behave. GLP-1 receptors (the target of semaglutide) are found on immune cells like neutrophils and eosinophils. When semaglutide activates these receptors, it can:

A 2023 study found that in patients having open-heart surgery, semaglutide reduced inflammation in the fat around the heart (epicardial fat). It did this by lowering the activity of neutrophils and making them less likely to stick to the blood vessel lining in that fat, which contains GLP-1 receptors.

Possible Long-Term Side Effects of Ozempic to Watch For

Large randomized and real-world analyses confirm that serious adverse events are uncommon relative to the number of people treated. The most frequent issues are gastrointestinal effects, and hypoglycemia is mainly a concern if you’re also on insulin or a sulfonylurea.

That said, long-term use means you should be aware of less common but clinically important risks:

1. Pancreatitis

In glycemic control trials, acute pancreatitis was confirmed in 7 Ozempic-treated patients compared to 3 patients in the comparator group. One patient on Ozempic developed chronic pancreatitis.

Symptoms of pancreatitis include:

• • Severe abdominal pain accompanied by nausea and vomiting
  • Abdominal tenderness, especially in the upper part
  • Fever
  • Rapid pulse
  • The abdomen might appear swollen or feel bloated
  • Loss of appetite
  • Unexplained weight loss

If any of these symptoms occur, seek medical attention immediately.

2. Kidney damage

There have been reports of acute kidney injury and worsening of chronic kidney failure in patients using GLP-1 receptor agonists like Ozempic. In some cases, this has required dialysis. These kidney issues can occur even if you don’t have prior kidney problems. Most cases involved severe nausea, vomiting, diarrhea, or dehydration.

A 2021 study investigated two cases where patients with CKD (due to diabetic kidney disease) experienced a rapid decline in kidney function after being prescribed semaglutide. Both patients saw their kidney function worsen significantly, with increased levels of protein in their urine, which is a sign of kidney damage.

In one patient, a kidney biopsy revealed severe kidney damage, including:

• • scarring (glomerulosclerosis)
  • inflammation
  • signs of acute injury to the kidney’s filtering units (tubules)

Monitor your kidney function, especially when starting or increasing your dose of Ozempic. Staying well-hydrated and promptly addressing any gastrointestinal symptoms can help reduce the risk of kidney complications.

3. Thyroid cancer risk

Ozempic carries a boxed warning about thyroid C-cell tumors seen in rodent studies. We don’t have evidence of a causal risk in humans, but it’s contraindicated if you have a personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Report neck masses, hoarseness, or trouble swallowing.

4. Hypoglycemia (mostly when combined with other meds)

On its own, Ozempic has a low hypoglycemia risk because its insulin effect is glucose-dependent. But if used alongside insulin therapy or sulfonylureas, it can increase the risk of hypoglycemia or low blood sugar.

In one analysis, researchers found that 16.5% of emergency department visits linked to semaglutide were due to hypoglycemia, and over a third of those cases (37.6%) required hospitalization.

Symptoms of hypoglycemia include:

• • shakiness
  • sweating
  • confusion
  • dizziness
  • loss of consciousness (in severe cases)

Monitor blood sugar levels frequently if you’re on a combined treatment regimen and discuss with your doctor how to adjust doses accordingly.

5. Gallbladder disease

GLP-1 RAs (including Ozempic) are associated with a higher risk of gallstones/cholecystitis, likely related to weight loss and biliary motility changes. In placebo-controlled trials, 1.5% of patients taking Ozempic 0.5 mg and 0.4% taking Ozempic 1 mg experienced gallstones, while no cases were reported in the placebo group.

The absolute risk is low, but you should seek care for persistent right-upper-quadrant pain, fever, or jaundice.

6. Diabetic retinopathy worsening (if you have pre-existing disease)

In SUSTAIN-6, semaglutide was linked to a higher rate of retinopathy complications vs placebo, especially in people with baseline retinopathy and rapid A1c drops. The best interpretation is that fast glucose improvement can transiently worsen retinopathy (a known phenomenon with intensive diabetes therapy), not that semaglutide directly damages eyes.

In the trial, people taking semaglutide had about a 76% higher risk of diabetic retinopathy complications than those on placebo, and most affected participants already had retinopathy at the start.

On the other hand, new or worsening kidney disease happened less often with semaglutide, 3.8% compared to 6.1% with placebo, a 36% lower risk.

If you have diabetic eye disease, arrange more frequent eye exams with your ophthalmologist during the first 6-12 months of A1c improvement.

7. Aspiration during surgery & anesthesia

Ozempic delays gastric emptying. For most people, this helps satiety, but for some, it causes nausea, fullness, or reflux. The American Society of Anesthesiologists (ASA) has identified delayed emptying as a relevant consideration prior to anesthesia and endoscopy.

The Ozempic label now warns clinicians to consider this risk. Many surgical teams now individualize the plan (e.g., special fasting instructions, sometimes holding a dose). Always inform your surgical/anesthesia team that you’re taking semaglutide.

Checklist to personalize your long-term Ozempic plan

Use this as your guide to get the most from Ozempic over the long term.

Recap

Long-term effects of Ozempic include better blood sugar control, weight loss, improved heart and kidney health, lower blood pressure, reduced LDL (“bad”) cholesterol, and decreased inflammation in various organs. Most side effects occur early and are manageable, while serious ones are rare but should be identified promptly.

Lasting success depends not only on starting treatment but also on staying consistent, monitoring your health, and having a plan if you decide to stop so you can maintain your progress.

Frequently Asked Questions